Zampeli E, Gizis M, Siakavellas SI, Bamias G. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(3): 293-303 [PMID: 25133030 DOI: 10.4291/wjgp.v5.i3.293]
Corresponding Author of This Article
Giorgos Bamias, Consultant in Gastroenterology, Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University of Athens, 17 Agiou Thoma st., 15235 Athens, Greece. gbamias@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pathophysiol. Aug 15, 2014; 5(3): 293-303 Published online Aug 15, 2014. doi: 10.4291/wjgp.v5.i3.293
Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis
Evanthia Zampeli, Michalis Gizis, Spyros I Siakavellas, Giorgos Bamias
Evanthia Zampeli, Gastroenterology Department, Alexandra General Hospital, 11528 Athens, Greece
Michalis Gizis, Spyros I Siakavellas, Giorgos Bamias, Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University of Athens, Laikon Hospital, 15235 Athens, Greece
Author contributions: Zampeli E, Gizis M and Siakavellas SI reviewed the literature; Zampeli E, Gizis M, Siakavellas SI and Bamias G analyzed the data; Zampeli E and Bamias G designed the structure of the review; Zampeli E and Bamias G wrote the paper.
Correspondence to: Giorgos Bamias, Consultant in Gastroenterology, Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University of Athens, 17 Agiou Thoma st., 15235 Athens, Greece. gbamias@gmail.com
Telephone: +30-21-06456504 Fax: +30-21-07791839
Received: January 4, 2014 Revised: March 7, 2014 Accepted: June 10, 2014 Published online: August 15, 2014 Processing time: 242 Days and 18.8 Hours
Core Tip
Core tip: The use of anti-tumor necrosis factor (TNF) monoclonal antibodies for the treatment of ulcerative colitis has been associated with high rates of primary and secondary non-response, important safety issues and considerable cost. Selection of patients with the highest probability to response to anti-TNF treatment would overcome these problems. Analysis of the pivotal trials and accumulated experience from clinical practice has led to the identification of certain prognostic factors for favorable or adverse outcomes. These include clinical and epidemiological parameters, biological markers of inflammation, endoscopic findings, molecular signatures and pharmacological factors. Incorporation of such predictors into the current therapeutic protocols may lead to the optimization of anti-TNF treatment in ulcerative colitis.
